BCAS1 (Breast Carcinoma Amplified Sequence 1) is widely recognized as a marker of newly formed, premyelinating and early myelinating oligodendrocytes in the central nervous system. Although initially identified because of its amplification in breast cancer [1], subsequent studies have established its predominant expression in the brain, particularly in regions undergoing active myelination or remyelination. BCAS1 expression is transient during oligodendrocyte maturation and declines as myelinating cells reach full maturity. In fetal brain BCAS1 positive oligodendrocytes are restricted to the white matter. In adult brains they persist in the grey matter until old age [2].
BCAS1 has been proposed to contribute to tumorigenesis and its expression has been found in neoplastic cells from non-CNS tissues, such as breast, prostate, pancreatic, colorectal and gastric cancer. BCAS1 also undergoes alternative splicing but the functional consequences of individual BCAS1 protein isoforms remain poorly characterized. The splice variant BCAS1-SV1 has been linked to high proliferation and migration rate in glioblastoma [3,4].
SYSY Antibodies has developed several BCAS1 antibodies against BCAS1 that recognize different BCAS1 isoforms.
For more information on protein expression pattern, please refer to the overview image in our SYSY Antibodies ATLAS.
